Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06077747

Lumbar Vein Embolization for Chronic Headaches With Nutcracker Physiology

The purpose of this research is to gather information on the safety and feasibility of coiling the lumbar vein for the treatment of chronic headaches in patients with Nutcracker physiology and retrograde lumbar vein flow with epidural venous plexus congestion. All patients are extensively evaluated by a headache trained Neurologist confirming high pressure headache refractory to other treatments.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic Florida

Jacksonville, Florida, 32224, United States

Location status: Recruiting

About this study

This is a feasibility, non-randomized, non-blinded clinical trial enrolling patients who are at least 18 years of age for the treatment of chronic headache in the setting of Nutcracker physiology with retrograde lumbar vein flow and epidural venous plexus enhancement.

Patients are initially evaluated by a fellowship trained headache neurologist to obtain a detailed headache history, VAS score, MIDAS score, and physical examination. They are also evaluated by a neuro ophthalmologist with fundoscopic examination to assess for disc edema. A lab work-up is performed including complete blood count, basic metabolic panel, and microscopic urinalysis. A lumbar puncture and imaging work-up are then obtained as well.

Patients will proceed to an MRI to evaluate for Nutcracker physiology, retrograde lumbar vein flow, and epidural venous plexus enhancement if they meet the following criteria:

  • Daily headache from onset lasting > 3 months
  • Headache described as pressure sensation
  • Headache worsened in the Trendelenburg position
  • MRI, MRA head and neck and MR venogram negative for possible secondary causes of headache including space occupying lesions, Chiari malformation, cerebral vein thrombosis, hydrocephalus, dissection, aneurysm etc

a. Transverse sinus stenosis is allowed to proceed

  • Exposed to CSF pressure/volume lowering medications

a. Tried 2 of 4 unless contraindications: acetazolamide, methazolamide, indomethacin SR or spironolactone) or CSF volume removal via LP with positive or neutral response

  • Failed at least 3 typical headache preventative medications from different classes: antidepressants, antiepileptic, and blood pressure If these criteria are met, they will undergo an MRI to evaluate for Nutcracker physiology, retrograde lumbar vein flow, and epidural venous plexus enhancement. For those patients that demonstrate Nutcracker physiology with retrograde lumbar vein flow and EVP enhancement they would be eligible for the clinical trial.

If they are interested in the clinical trial, they will be evaluated in clinic by a fellowship trained interventional radiologist to review the following:

  • Procedural sedation: moderate sedation versus general anesthesia
  • Prior contrast allergies
  • Consent for procedure
  • Prior to venography the patient is taken off all headache medications for 4 weeks.

For patients that are still eligible and interested they will proceed with venography. Venography involves an evaluation of the left renal vein and left lumbar vein to confirm the findings on the MRI. If catheter-based venography confirms Nutcracker physiology with retrograde lumbar vein flow and epidural venous plexus enhancement they will then enter the clinical trial. Embolization of the lumbar vein will be performed. A follow-up venogram will then be performed to ensure there is no further retrograde lumbar vein flow.

After the embolization patient's will be followed for symptom evaluation at 1,3,7,14, and 28 days after the procedure and then monthly. They will also have a follow-up physical examination at 1 month, 3 months, 6 months and then every 6 months post-procedure. They will be followed for a total of 18 months. Some patients may need follow-up laboratory work-up and MRI post-procedure as standard of care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Daily headache from onset lasting > 3 months.
  • Headache described as pressure sensation.
  • Headache worsened in the Trendelenburg position.
  • Exposed to CSF pressure/volume lowering medications.
  • Tried 2 of 4 unless contraindications: acetazolamide, methazolamide, indomethacin SR or spironolactone) or CSF volume removal via LP with positive or neutral response.
  • Failed at least 3 typical headache preventative medications from different classes-antidepressants, antiepileptic, blood pressure medications.
  • MRI demonstrates that Nutcracker physiology is present.
  • Decreased SMA angle, renal vein narrowing, decreased AMD.
  • Retrograde lumbar vein flow and early EVP enhancement.
  • Ability to understand study procedures and to comply with them for the entire length of the study.
  • Negative pregnancy test.

Exclusion criteria

  • Evidence of disc edema.
  • Positive urinalysis for hematuria or proteinuria.
  • Abnormal CBC or CMP.
  • MRI, MRA head and neck and MR venogram with a possible secondary causes of headache including space occupying lesions, Chiari malformation, cerebral vein thrombosis, hydrocephalus, dissection, aneurysm etc.

Treatment and study plan

Coil Embolization of the Lumbar Vein

Procedure

Catheter based venography will first confirm Nutcracker physiology with retrograde lumbar vein flow and epidural venous plexus congestion. The lumbar vein will then be coil embolized.

Primary outcomes

  1. Change in headache pain

    Time frame: 1,3,7,14, and 28 days after the procedure and then monthly for 17 months

    Measured by a visual analogue scale (VAS) where 0 = no pain, 5= moderate pain, 10= worst pain

  2. Change in Migraine Disability Assessment

    Time frame: 1,3,7,14, and 28 days after the procedure and then monthly for 17 months

    Measured by the Migraine Disability Assessment Test

Secondary outcomes

  1. Adverse Events

    Time frame: 1,3,7,14, and 28 days after the procedure and then monthly for 17 months

    Number of adverse events defined as any unwanted symptom that occurred from embolizing the lumbar vein such as flank pain, proteinuria, hematuria, or pelvic congestion.

  2. Serious Adverse Events

    Time frame: 1,3,7,14, and 28 days after the procedure and then monthly for 17 months

    Number of serious adverse events defined as any serious unexpected complication during or after the embolization that would result in death, is life threatening, requires prolonged hospitalization, causes persistent or significant disability or incapacity, or another condition that represents significant hazards.

Study contacts

Contact information is provided by the study sponsor or research team.

Julia Santos

CONTACT

[email protected]

904-953-3280

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Lumbar Vein Embolization for the Treatment of Chronic Headache in Patients With Nutcracker Physiology and Retrograde Lumbar Vein Flow With Epidural Venous Plexus Enhancement

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Oct 11, 2023
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.